RetaMaps Editorial· Updated October 1, 2026· Editorial review · Medical review pending
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 1, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
There is no retatrutide price, because there is no retatrutide product.
It isn't FDA-approved, has no brand name, and Lilly hasn't announced pricing.
Any site quoting a retatrutide price today is either guessing or selling
something that isn't the real medication. [3]
The one real pricing signal: Lilly's own precedent
The most honest basis for projection is how Lilly priced its newest obesity
medication. Foundayo (orforglipron), approved April 1, 2026, launched on
LillyDirect at $149–$349 per month self-pay, and $25 per month for
eligible commercially insured patients. [1]
Unknown. If approved (~submission planned Q1 2027 [2]), it enters a market already crowded with tirzepatide, semaglutide and oral options — competitive pressure, injectable manufacturing costs, and its positioning as the most effective agent will all pull on the price.
Insurance is the bigger unknown: coverage for obesity medications varies
widely by plan and is actively shifting, and retatrutide's coverage will
depend on its approved indications. Anything more specific than that is
speculation, so we won't print it.
"Cheap reta" offers are the scam signal, not the deal. No legitimate
retatrutide is for sale at any price. The FDA states retatrutide cannot be
used in compounding under federal law and has issued warning letters to
sellers of "research" products [3]; Lilly sued six U.S. sellers in
August 2026 and says it has flagged 200+ entities to the FDA. [4]
See the research-peptide warning.
RetaMaps will publish real numbers the day they exist — the
FDA approval tracker is where that lands first.
Unknowable before approval and labeling. Coverage for current GLP-1 weight medications varies widely by plan; retatrutide's coverage will depend on its approved indications and payer decisions after launch. Any coverage claim today is a projection.
Why is 'cheap retatrutide' online a red flag?
Because no legitimate retatrutide is for sale at any price. The FDA says retatrutide cannot be used in compounding under federal law and has sent warning letters to sellers; Lilly has sued six U.S. sellers. Whatever is in those vials, it is not approved, tested retatrutide.
Can a doctor get me retatrutide early?
Only by enrolling you in a clinical trial or through Lilly's expanded access program, which requires your physician to apply and meet medical criteria — neither of which involves buying the drug.
Find weight-loss providers near you
Browse the practices RetaMaps tracks, or get an email when retatrutide's status changes.